Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTORPHANOL TARTRATE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Management of moderate to severe pain,Preoperative medication,Supplement to balanced anesthesia,Relief of pain during labor,Off-label: Migraine headache (via intranasal route)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is 2.5-3.5 hours (mean ~3 hours) in adults; prolonged in hepatic impairment (up to 5-6 hours) and renal impairment (variable, may increase).
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Butorphanol is extensively metabolized in the liver via hydroxylation and N-dealkylation, primarily by CYP3A4. The major metabolite is hydroxybutorphanol, which has some analgesic activity but is less potent.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for approximately 70-80% of elimination (mostly metabolites), with 15-20% via feces (biliary). Less than 5% excreted unchanged in urine.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 80% bound to plasma proteins (mainly alpha-1-acid glycoprotein and albumin).
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Vd: 4-5 L/kg (range 3-6 L/kg), indicating extensive tissue distribution, including CNS.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Intranasal: 60-70% (range 48-80%); IM: 80-100% (complete but variable); Oral: very low (<5%) due to extensive first-pass metabolism; not used orally.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No specific guidelines for dose adjustment in renal impairment; use with caution. For severe renal impairment (e GFR <30 m L/min), consider reducing dose and/or extending dosing interval due to potential accumulation of active metabolites.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50% and monitor for excessive sedation. Class C: Avoid use or reduce dose to 25% of normal and monitor closely.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Weight-based: 0.01-0.02 mg/kg intravenously or intramuscularly every 3-4 hours as needed; maximum single dose 1 mg. For intranasal: 1 mg as a single dose in patients ≥18 kg (for migraine). Not recommended for PCA in children.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Reduce initial dose by 50% (e.g., 0.5-1 mg IV/IM every 4-6 hours); titrate cautiously due to increased sensitivity to opioid effects and risk of respiratory depression. For intranasal, consider lower dose (0.5 mg). Monitor renal function.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Concomitant use of opioids with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Respiratory depression: especially in patients with compromised respiratory function or when used with other CNS depressants,Dependence and abuse liability: Schedule IV controlled substance,Increases in intracranial pressure: may exacerbate in patients with head injury,Cardiovascular effects: may increase cardiac workload and should be avoided in acute MI,Biliary tract spasm: may cause spasm of the sphincter of Oddi,Withdrawal: may precipitate withdrawal in opioid-dependent patients if given shortly after other mu-agonists
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to butorphanol tartrate or any component of the formulation,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Known or suspected gastrointestinal obstruction,Patients who are physically dependent on mu-agonists due to risk of acute withdrawal
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid alcohol and grapefruit juice (may increase butorphanol levels). No specific food restrictions.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis produced increased fetal resorptions and decreased fetal weights at doses 3-6 times the human therapeutic dose. In the first trimester, risks cannot be ruled out. In the second and third trimesters, prolonged use may cause neonatal opioid withdrawal syndrome. Use near term may cause respiratory depression in the neonate.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Butorphanol is excreted into human milk. The milk-to-plasma ratio (M/P) is approximately 0.7. Limited data suggest low levels; however, due to potential for serious adverse reactions in nursing infants, caution should be exercised. The manufacturer recommends avoiding use while breastfeeding.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Pregnancy may alter butorphanol pharmacokinetics due to increased plasma volume and enhanced clearance. However, specific dose adjustment recommendations are not established. Use lowest effective dose for shortest duration. For labor analgesia, standard IV/IM doses (1-2 mg) may be used, but monitor for maternal and neonatal respiratory depression.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Butorphanol is a mixed agonist-antagonist opioid; may precipitate withdrawal in opioid-dependent patients. Ceiling effect on respiratory depression. Higher risk of psychotomimetic effects (dysphoria, hallucinations) compared to morphine. Onset: 1-2 min IV, 5-10 min IM; duration 3-4 hours. Nasal spray has bioavailability ~70%.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
May cause drowsiness or dizziness; avoid driving or operating machinery.,Do not take with alcohol or other CNS depressants.,Can cause nausea, vomiting, or sweating; report severe reactions.,Use exactly as prescribed; risk of dependence with long-term use.,If you are dependent on opioids, this drug may cause withdrawal symptoms.,Notify your doctor if you have a history of head injury, asthma, or liver/kidney disease.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Butorphanol, a mixed agonist-antagonist opioid, and dimenhydrinate, a histamine H1 antagonist, exhibit additive central nervous system (CNS) depression. Concurrent use increases the risk of profound sedation, respiratory depression, dizziness, and psychomotor impairment. These effects are dose-dependent and can lead to hazardous outcomes such as falls, respiratory compromise, or coma, particularly in elderly or debilitated patients."
"Concomitant use of butorphanol, a mixed agonist-antagonist opioid, with pipotiazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression, including sedation, respiratory depression, and hypotension. Pipotiazine may also potentiate the analgesic effects of butorphanol through antagonism at dopamine D2 receptors, but this combination increases the risk of extrapyramidal symptoms and neuroleptic malignant syndrome. Clinically, patients may experience excessive sedation, confusion, orthostatic hypotension, and impaired psychomotor function."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTORPHANOL TARTRATE vs ACTIQ, answered by our medical review team.
BUTORPHANOL TARTRATE is a Opioid Analgesic that works by Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTORPHANOL TARTRATE and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTORPHANOL TARTRATE is: 1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTORPHANOL TARTRATE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTORPHANOL TARTRATE is classified as Category C. Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis . ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.